21st European Congress on Alternatives to Animal Testing, September 23-26 2018, University of Linz, Austria

Oral presentations per session
(including date and time slots)

(preliminary, vers. 04.09.2018)

K1 Opening & Keynote Lecture I (plenary)
Sunday, 23 September 2018
13:00-13:45
    Welcome addresses
    Application of Human Multi-Organ-Chips to Enhance Safety and Efficacy Assessment in Drug Discovery
Reyk Horland
Vice-President, TissUse GmbH,
DE-Berlin
K2 Keynote Lecture II (plenary)
Monday, 24 September 2018
09:00-09:30
    The Netherlands Initiative "Phasing out the Use of Experimental Animals within a 10 Year Period?"
Herman B.W.M. Koëter
Managing Director, Orange House Partnership, BE-Brussels & Chairman of NCad, the Netherlands National Committee for the protection of animals used for scientific purposes (NCad), NL-The Hague
K3 Keynote Lecture III (plenary)
Tuesday, 25 September 2018
09:00-09:30
    Generating Human Organ Models by 3D Bioprinting
Jens Kurreck
Director, Inst. Biotechnology, Applied Biochemistry, TU Berlin,
DE-Berlin
K4 Keynote Lecture IV (plenary)
Wednesday, 26 September 2018
09:00-09:30
    Having a Successful Career in in vitro Toxicology: Pillars of Success
Helena Kandarova
Executive Director, MatTek IVLSL (In Vitro Life Science Laboratories),
SK-Bratislava
(The topic 3D Models & Multi-Organ Chips (MOC), Human-Organ-Chips (HOC) is sponsored by the Lush Prize)
1.1 3D Models & Multi-Organ-Chips (MOC), Human-Organ-Chips (HOC) I - Perfusion & Lung
Sunday, 23 September 2018
13:50-15.20
11   Bioprinting Perfusion-Enabled Liver Equivalents for Advanced Organ-on-a-Chip Applications
Tobias Grix, DE-Berlin
70   Characterization of a lung/liver organ-on-a-chip model
David Bovard, CH-Neuchâtel
75   3D bioprinting of lung and liver models for viral infection and transduction with viral gene vectors
Johanna Berg, DE-Berlin
285   Lung-on-a-Chip: The interplay of primary human epithelial and endothelial cells improves the alveolar barrier function
Andreas Stucki, CH-Bern
231   Microfluidic engineering of vascular networks by growth factor gradient control
Barbara Bachmann, AT-Vienna
1.2 3D Models & Multi-Organ-Chips (MOC), Human-Organ-Chips (HOC) II - Woundhealing - Bone & Skin
Monday, 24 September 2018
09:35-11:05
46   Development of an in vitro human-based multicomponent 3D joint model as basis for the simulation of an arthritic joint model
Alexandra Damerau, DE-Berlin
50   Mimicking the initial phase of fracture healing in vitro
Moritz Pfeiffenberger, DE-Berlin
148   Re-epithelialization in Focus: Non-invasive Monitoring of Epidermal Wound Closure in Vitro Using Organotypic Skin Models
Lisa Kiesewetter, DE-Würzburg
238   Cartilage-on-a-Chip: the future of osteoarthritis modeling and drug screening?
Julie Rosser, AT-Vienna
228   Utilization of in vitro and ex vivo wound healing models to address different aspects of cutaneous wound healing and drug testing
Johanna Brandner, DE-Hamburg
1.3 3D Models & Multi-Organ-Chips (MOC), Human-Organ-Chips (HOC) III - Specific Organs
Monday, 24 September 2018
11:35-13:05
96   Retina-on-a-Chip: Merging Organoid and Organ-on-a-Chip technology for complex multi-layer tissue models
Christopher Probst, DE-Stuttgart
284   Merging high-content and higher-throughput screening: Microphysiological Organ-on-a-Chip systems integrating human retinal, cardiac and adipose tissue
Peter Loskill, DE-Stuttgart
102   Development of a multi-organ in vitro model of the interactions between liver and cardiac cells under uni-directional dynamic flow
Bhumika Singh, GB-Rotherham
211   Characterization of chemical metabolism in combined skin and liver models over extended and repeated exposure in a multi organ chip device
Jochen Kühnl, DE-Hamburg
1.4 3D Models & Multi-Organ-Chips (MOC), Human-Organ-Chips (HOC) IV - Intestinal Systems
Tuesday, 25 September 2018
14:00-15:30
36   Emulating the Gut-Liver Axis - Organ-on-chip as Translational Tool in Sepsis Research
Martin Raasch, DE-Jena
263   Reconstructed 3D Model of Human Small Intestine for Prediction Of Gastrointestinal Toxicity and Drug Absorption
Jan Markus, SK-Bratislava
120   Human intestinal organoids as model for studying drug transport
Tamara Zietek, DE-Cologne
178   High-throughput, perfused intestinal tubules for real-time assessment of drug-induced barrier disruption
Karlijn Wilschut, NL-Leiden
1.5 3D Models & Multi-Organ-Chips (MOC), Human-Organ-Chips (HOC) V - Future Applications
Tuesday, 25 September 2018
16:00-17:30
204   Tomorrow today: organ-on-a-chip advances towards clinically relevant pharmaceutical and medical in vitro models
Peter Ertl, AT-Vienna
278   Microphysiological flux balance platform unravels the dynamics of drug induced steatosis
Muneef Ayyash, IL-Jerusalem
223   Importance of computational modelling in the design of Organ on a Chip Devices
Bhumika Singh, GB-Rotherham
208   Impact of Spheroidal Age on Drug Toxicity and Diffusivity
Christoph Eilenberger, AT-Vienna
275   3D Models and Multi-Organ-Chips: Scaffold-free 3D tissue models – from static to microphysiological applications
Oliver Frei, CH-Schlieren
2.1 3R Centers in Europe - National and Local Centers - part I
Monday, 24 September 2018
14:00-15:30
271   The National Centre for the 3Rs
Jan Ragan, GB-London
192   Swiss 3R Competence Centre: Promoting research & education on 3Rs
Chantra Eskes, CH-Bern
100   Towards implementation of the 3Rs in basic research and teaching in Italy: Centro 3R
Arti Ahluwalia, IT-Pisa
269   The Slovak National Platform for 3Rs - SNP 3Rs
Helena Kandarova, SK-Bratislava
199   National Committees under Directive 2010/63/EU and Three Rs centres – complementing one another for a win-win
Susanna Louhimies, BE-Brussels
2.2 3R Centers in Europe - National and Local Centers - part II
Monday, 24 September 2018
16:00-17:30

221   Collaboration and complementarity within Three Rs centres
Adelaide Dura, IT-Ispra
216   Berlin – Bundling 3R Expertise in the German Capital
Monika Schäfer-Korting, DE-Berlin
99   Animal protection and 3R in Switzerland
Julika Fitzi-Rathgen, CH-Basel
76   3Rs at the University of Zurich
Paulin Jirkof, CH-Zurich
113   'ICar3R' - a New Interdisciplinary Centre for 3Rs in Animal Research of the Justus Liebig University Giessen
Stephanie Krämer, DE-Giessen
196   MUI animalFree Research Cluster
Doris Wilflingseder, AT-Innsbruck
paid advertising

Banner MatTek

3.1 3Rs in Education and Academia - Creating Awareness by Education and Training to Enhance Animal Welfare in Science
Monday, 24 September 2018
09:35-11:05
240   Alternative approaches in education provide excellent refinement measures
Christa Thöne-Reineke, DE-Berlin
54   ReThink3R: Design Thinking Workshops for Young Scientists – Awareness and Innovation for the 3Rs
Laura Behm, DE-Potsdam
55   Practical Guidance in LAS-Continuing Professional Development
Pieter Verbost, NL-Utrecht
74   The Laboratory Animal Science and Welfare course at University of Debrecen
Ádám Deák, HU-Debrecen
122   Animal welfare right from the start: The 3Rs concept as a guiding principle in veterinary training
Stephanie Krämer, DE-Giessen
183   ‘Everyone is responsible’ - animal welfare in the education
Györgyi Szabó, HU-Budapest
3.2 3Rs in Education and Academia - Teaching and Applying Alternatives in Education and Training
Tuesday, 25 September 2018

09:35-11:05
147   Training and Teaching in Substitutive Approaches to Animal Testing: the commitment of Italian Academia
Anna Maria Bassi, IT-Genova 
98   Implementation of 3R in veterinary education through virtual patients
Lena Vogt, DE-Berlin 
104   Towards animal -free methods in education and training: Lessons from healthcare
Luisa Bastos, BE-Brussels 
224   Lung Simulation – An Alternative Approach to Animal Testing for Applications in Aerosol and Respiratory Research
Mathias Forjan, AT-Vienna 
111   Teaching 3R principles in ecotoxicology by performing a problem-based learning project
Rita Leitner, AT-Vienna
270   The Alternatives in Education and Academia: what is happening across EU
Candida Nastrucci, IT-Rome 
4 Advanced Safety Testing of Cosmetics and Consumer Products
Sunday, 23 September 2018
16:00-17:30

273   Newly validated 3D skin genotoxicity assays improve safety assessments of cosmetic ingredients
Rodger Curren, US-Gaithersburg
265   Inter-and intra-laboratory reproducibility of the in vitro photo-toxicity test using 3D reconstructed human epidermis model EpiDerm
Helena Kandarova, SK-Bratislava
91   Inconsistent effects of chemical filters in UV/ROS stress cell models
Stefanie Hofer, AT-Innsbruck
110   European Institutions Still Need to Close the Door on Animal-Tested Cosmetics
Julia Baines, GB-London
5 Alternatives to Animal Testing in Food Safety, Nutrition and Efficacy
Sunday, 23 September 2018
13:50-15:20

229   More animal testing for less human safety? How animals continue to suffer for our (novel) food and why oral toxicity tests should be replaced
Tilo Weber, DE-Neubiberg
201   In vitro fluid-dynamic intestinal device as fast and reliable approach for food nutrients permeation tests
Silvia Scaglione, IT-Genova
24   Methodological Improvements and Automation for Better Biodetection of Endocrine Activities In-Vitro
Karma Fussell
, CH-Lausanne
6 Biological Barriers
Tuesday, 25 September 2018
09:35-11:05

56   Development of an advanced primary in vitro model of the human small intestine
Matthias Schweinlin, DE-Würzburg
189   iPSC-derived renal proximal tubular cells: development and evaluation for their application in nephrotoxicity studies
Anja Wilmes, NL-Amsterdam
107   An improved in vitro model of the oral mucosa epithelium for biomarker research and transport studies: Optimization by media supplements and airlift cultivation
Grace Lin, AT-Vienna
154   Genetically modified 3D human in vitro lung models
Samual Constant, CH-Plan-les-Ouates
212   Microfluidic strategies for nanomaterial risk assessment at in vitro organ barrier models
Mario Rothbauer, AT-Vienna
131   Human induced pluripotent stem cell based in vitro models of the blood-brain barrier: A promise for the future of drug testing, toxicity and disease modelling
Winfried Neuhaus
, AT-Vienna
7.1 Disease Models Using HUMAN Cells, Tissues and Organs - Tumors & Other Disease Models
Monday, 24 September 2018
16:00-17:30

2   A combined in silico-3D lung tumor model to understand network effects of driver mutations for targeted therapy predictions
Gudrun Dandekar, DE-Würzburg 
237   Establishment of a New Cholangiocarcinoma Cell Line MUG-CCArly1
Florian Kleinegger, AT-Graz 
241   Investigation on ex-vivo functional interactions between tumor cells and lymphoblastoid cells in chordoma
Beate Rinner, AT-Graz 
274   Disease models using human cells: 3D in-vitro models for metabolic diseases show translation in diabetes and liver fibrosis
Patrick Guye, CH-Schlieren 
253   Extracellular Vesicles – Mighty Players in Chordoma Communication?
Ines Anders, AT-Graz
7.2 Disease Models Using HUMAN Cells, Tissues and Organs - Lung & Infection
Tuesday, 25 September 2018
16:00-17:30

93   A human lung ex vivo infection model
Stefan Hippenstiel, DE-Berlin
168   Human cell- and tissue-based models of the lungs in state of health and disease
Nicole Schneider-Daum, DE-Saarbrücken
173   Modeling respiratory bacterial infections using in vitro human airway epithelia
Samual Constant, CH-Plan-les-Ouates
85   3D Epithelial Culture Model to Study Chlamydia Infection
Munir Al-Zeer, DE-Berlin
136   hAELVi cells as an in vitro inflammation model
Julia Katharina Metz, DE-Saarbrücken
7.3 Disease Models Using HUMAN Cells, Tissues and Organs - Skin Tumor Models
Wednesday, 26 September 2018
11:35
-13:05
219   Normal human skin and atopic dermatitis models – penetration and efficacy of topical glucocorticoids
Monika Schäfer-Korting, DE-Berlin
279   Human cell-based tumor microenvironment models for improved preclinical drug development
Christian Zoschke, DE-Berlin
203   3D melanoma skin models: unravelling the effects of the basal membrane and sub-populations of fibroblasts in tumour progression and invasion
Abdoel El Ghalbzouri, NL-Leiden
258   Unusual, innovative, and close to in-vivo: MUG-Mel1 and MUG-Mel2 melanoma cell lines for drug development
Beate Rinner, AT-Graz
8.1 Ecotoxicology I - Focus on diverse ecotoxicological endpoints
Monday, 24 September 2018
14:00-15:30

45   Ecological Threshold for Toxicological Concern (eco-TTC) - Applications for Environmental Risk Assessment in Various Contexts
Marlies Halder, IT-Ispra
62   Prediction of acute fish toxicity of fragrance chemicals: the RTgill-W1 cell assay as a simple, accurate and reliable alternative to the fish in vivo test
Lu Hostettler, CH-Dübendorf
146   FISH on CHIPS: Development of a novel in vitro system of the fish intestine
Carolin Drieschner, CH-Dübendorf
186   Predicting chemical impact on fish growth by combining computational modelling with in vitro fish cell line responses
Kristin Schirmer, CH-Dübendorf
65    Using mechanisms of toxic action to classify and predict ester ecotoxicity
Pascal Bicherel, FR-L’Isle D’Abeau
8.2 Ecotoxicology II - Focus on metabolism and bioaccumulation
Tuesday, 25 September 2018
09:35-11:05

187   Ability of three rainbow trout (Onchorhynchus mykiss) cell lines to eliminate benzo(a)pyrene and extrapolation to derive a fish bioconcentration factor
Kristin Schirmer, CH-Dübendorf
87   Xenobiotic metabolism in the fish hepatic cell lines Hepa-E1 and RTH-149, and the gill cell lines RTgill-W1 and G1B: biomarkers of CYP450 activity and oxidative stress
Marco Franco, US-Waco
69   Comparability of the in vitro RTgutGC (Rainbow trout) intestinal cell line to native gastrointestinal tissue
Laura Langan, GB-Plymouth
58   Tissue specific response of organoids to the model compound pyrene in rainbow trout 3D co-cultures
Laura Langan, GB-Plymouth
90   Development of OECD Test Guidelines and Guidance Document on determination of fish in vitro hepatic clearance
Marlies Halder
, IT-Ispra
63   Benchmarking study to support regulatory acceptance of the application of in vitro-in vivo extrapolation to predict the bioaccumulation potential of fragrance chemicals
Lu Hostettler, CH-Dübendorf
9 Efficacy and Safety Testing of Drugs, Medical Devices & Biopharmaceutics
Monday, 24 September 2018
16:00-17:30

9   Using a concerted analysis of corresponding cellular assays to create a complete in vitro bone culture and implant testing system
Daniel Seitz, DE-Bayreuth
126   3D in vitro cardiac model established from fish larvae for application in pharmacology
Bianka Grunow, DE-Dummerstorf
172   Efficacy testing of antivirals using human upper and small airway epithelia
Samual Constant, CH-Plan-les-Ouates
266   Successful Development and Validation of the EpiDerm In Vitro Skin Irritation Protocol for the Assessment of Medical Devices extracts
Helena Kandarova, SK-Bratislava
8   The Nonclinical Innovation and Patient Safety Initiative (NIPSI): Supporting Human-Based Nonclinical Approaches Through Advances in Law, Policy, Education and Training in the United States
Elizabeth Baker
, US-Washington
156   Rapid Development of anti-idiotypic binders using a novel affinity scaffold
Toni Hoffmann
, GB-Wetherby
10 Free Communications
Tuesday, 25 September 2018
11:35-13:05

105   Cellular senescence: a response pathway within AOPs?
Johannes Grillari, AT-Vienna
137   Gene edited non-human primates (NHPs) – further ethical challenges. And the responsibility of scientific journals
Ismene Fertschai, AT-Graz
12   Comparative analysis of the difference of toxicity test between Chinese and European Pharmacopoeia
Mao Ling Wei, CN-Chengdu
123   A review of REACH from the animal perspective
Katy Taylor, GB-London
11 In Silico Models: Toxicology & Efficacy of Drugs, Chemicals & Cosmetics
Tuesday, 25 September 2018
11:35-13:05

21   In Silico Tools to Assist the Development of Physiologically-Based Kinetic Models: Identification, Characterisation and Use
Judith Madden, GB-Liverpool
22   Computational Methods for the Prediction of Chemical Toxicity
Priyanka Banerjee, DE-Berlin
124   Modelling oxygen consumption in brain organoids
Arti Ahluwalia, IT-Pisa
163   In-silico tool to design cyp3a5 silensomestm using T-5 substrate and lapatinib as mechanism-based inhibitor
Ashwani Sharma, FR-Saint-Grégoire
230   An in Silico Lung Tumor Model for Drug Efficacy Screening and Optimal Clinical Therapy as Alternative to Animal Testing
Meik Kunz, DE-Würzburg
 paid advertising

Banner evercyte

12 International Progress in 3Rs Research
Sunday, 23 September 2018
16:00-17:30

86   Predictive Toxicology, Strategies for Implementing New Approaches Outcomes of the 7th Annual Meeting of the American Society for Cellular and Computational Toxicology
Erin Hill, US-Gaithersburg
134   Consensus Ways of Alternative to Animal Testing in China
Shu Jun Cheng
, CN-Shanghai
7   3Rs Centre in Sri Lanka to promote 'Replacement' concept
Stefanie Schindler
, CH-Bern
    INDIA: Launching of a National Society for Alternatives to Animal Experiments
Mohammad A. Akbarsha
, IN-Tiruchirappalli
13 In vitro Techniques for CNS Toxicity and Disease Studies
Tuesday, 25 September 2018

11:35-13:05
213   Stem cell-based human blood-brain barrier co-culture models for pre-clinical development
Marco Metzger
, DE-Würzburg
108   Advanced human in vitro blood-brain barrier disease models for cerebral ischemia
Anna Gerhartl, AT-Vienna
4   Modelling ischemic stroke injury at the blood-brain barrier in vitro using induced pluripotent stem cells
Abraham Alahmad, US-Amarillo
177   Microfluidic-embedded 3D networks of iPSC-derived neurons and glia, for highly-predictive mechanistic neurotoxicity screening
Karlijn Wilschut, NL-Leiden
248   Microelectrode array (MEA) recordings of neuronal activity as in vitro tool to assess acute and developmental neurotoxicity
Remco Westerink, NL-Utrecht
14.1 Refinement & Reduction I- Culture of Care and Translational Research
Monday, 24 September 2018
11:35-13:05

198   Culture of Care – from words to action
Susanna Louhimies, BE-Brussels
94   Measuring fecal testosterone metabolites in house mice: replacement of invasive techniques
Kerstin E- Thonhauser, AT-Vienna
61   Different cultures of care for lab animals – a comparative study of practices at universities and private research institutions in Denmark
Thomas Lund, DK-Frederiksberg
5   Measuring Culture of Care – a practical example
Thomas Bertelsen, DK-Maaloev
81   Rehoming of former laboratory animals
Henriette Bout, NL-Den Haag
226   Translational failures call for critical appraisal of animal studies
Kathrin Herrmann, US-Baltimore
14.2 Refinement & Reduction II - Refinement and Avoidance of Severe Suffering
Tuesday, 25 September 2018
14:00-15:30

10   Systematic Assessment of Well-Being in Mice for Procedures Using General Anesthesia
Katharina Hohlbaum, DE-Berlin
109   Evaluating tramadol and buprenorphine applied via the drinking water as pain medication in a mouse osteotomy model
Mattea Durst, CH-Zurich
209   Animal Centric Strategies for Severity Assessment and Refinement
Lars Lewejohann, DE-Berlin
18   Focus on severe suffering: how reducing suffering can be a gateway to replacement
Elliot Lilley, GB-Horsham
195   Refinement by systematic severity scorings in animal experiments
Kristina Ullmann, DE-Berlin
235   Minimising suffering in energy deprived rats
Majken Dalgaard, DK-Måløv
14.3 Refinement & Reduction III - Increase Transparency and Use Existing Infrastructures to Reduce the Lab Animal Usage
Wednesday, 26 September 2018
09:35
-11:05
38   Sharing is Caring – Update on innovative approaches to share organs and tissues to reduce the lab animal usage
Annemarie Lang, DE-Berlin
1   The elephant in the room: PREPARE before you ARRIVE
Adrian Smith
, NO-Oslo
112   It´s time to rethink: learn from negative results in animal based research! Critical Incident Reporting System in Laboratory Animal Science CIRS-LAS.DE
Sabine Bischoff
, DE-Jena
132   Promoting transparency in preclinical research: preregistration of preclinical studies on www.preclinicaltrials.eu
Mira van der Naald
, NL-Utrecht
37   The Horse as Model for Osteoarthritis Research – Research Tools vs. Stakeholders
Annemarie Lang, DE-Berlin
15 Replacement – Advanced Technologies for Implementation of 3Rs
Monday, 24 September 2018
14:00-15:30

64   Patient-specific, additively manufactured vascular models enabling an animal-free neurointerventional training setup
Juliane Kuhl, DE-Hamburg
184   A biotechnological metabolic activation system – Potential for replacing rat liver S9 fractions
Andreas Schiwy, DE-Aachen
77   Development of an additive manufactured mouse phantom for quality assurance of a small animal irradiation device
Marie F. E. Wegner, DE-Hamburg
32   Metabolome analysis in vitro in NRK-52e cells might allow the prediction of nephrotoxicity and its mode of action
Barbara Birk, DE-Ludwigshafen
260   Establishment of a model for Equine Grass Sickness: extracorporeal blood perfusion of equine ileum
 Maria Unterköfler, AT-Vienna
16.1 Specific Endpoints of Toxicity I
Tuesday, 25 September 2018
16:00-17:30

31   Evaluation of retinoic acid receptor alpha (RARα) interaction of chemicals by combining two techniques to a new screening approach
Barbara Birk, DE-Ludwigshafen
35   Non-animal methods for skin sensitisation testing - is there really a need for integrated testing strategies?
David Roberts, GB-Liverpool
118   Pre-validation of an Acute Inhalation Toxicity Test Using the EpiAirway In Vitro Human Airway Model
Silvia Letasiova, SK-Bratislava
121   The added value of the 90-day repeated dose test for substances of low (sub) acute toxicity for REACH purposes
Katy Taylor, GB-London
16.2 Specific Endpoints of Toxicity II
Wednesday, 26 September 2018
09:35
-11:05
215   Impedance spectroscopy as a method to discriminate between all GHS categories for eye irritation in vitro
Christian Lotz, DE-Würzburg
247   Integrating Knowledge Of Carcinogenicity Adverse Outcome Pathways (AOPs) With Experimental Data
Steven Kane, GB-Leeds
286   In vitro methods for identifying substances with endocrine disruption potential
Marketa Dvorakova, CZ-Prague
30   Persistent endocrine-disrupting chemicals found in human follicular fluid stimulate proliferation of granulosa tumor via IGF1R - 3D cell culture model
Justyna Gogola, PL-Krakow
17 Stem Cell Models (hiPS, ES, mES, miPS)
Tuesday, 25 September 2018
14:00-15:30

144   Modelling sporadic Alzheimer's disease using patient derived iPSCs
Andras Dinnyes, HU-Godollo
236   Alternative research methods for challenging disease: human iPS derived Parkinson’s-on-chip
Julie Rosser, AT-Vienna
155   A new approach for animal free carcinogenicity testing using MN as biomarker (PMNvit)
Bastian Niklas Hölzel, DE-Aarbergen
165   Carp Stem Cells Growth on Chorioallantoic Membrane of Fertilized Hen's Egg
Mahmoud Galal, EG-Cairo
200   Modeling sex differences in vitro
Judith Lechner, AT-Innsbruck
18 Update on Implementing EU Dir 63/2010
Monday, 24 September 2018
09:35-11:05
197   Directive 2010/63/EU – progress, challenges and future directions
Susanna Louhimies, BE-Brussels
92   Transition to animal-free research - on possibilities for phasing out animal experiments and stimulating animal-free innovation
Henriette Bout, NL-Den Haag
95   Understanding and implementation of the 3Rs of animal welfare bodies at German research facilities and universities
Carolin Spicher, DE-Munich
16   Meta-analysis of NTSs ameliorates identification of research areas for 3R development
Bettina Bert, DE-Berlin
160   Severity classification: curse or blessing?
Anne Zintzsch, DE-Giessen
242   Decision making on the possible handling of laboratory animals after a trial
Mechthild Ladwig-Wiegard, DE-Berlin
paid advertising

Banner InSphero

19 Vaccines & The 3Rs: New Methods and Developments (e.g. Batch Release Testing)
Monday, 24 September 2018

11:35-13:05
101   Human Rabies vaccine glycoprotein G ELISA as an alternative to the challenge test: selection of a candidate method and future strategies
Jean Michel Chapsal, BE-Brussels
116   Development of an in vitro potency assay for Zika Purified Inactivated Vaccine (ZPIV)
Stephanie Richard, FR-Marcy l'Etoile
145   Vaccine batch to vaccine batch comparison by consistency testing (VAC2VAC)
Hilde Depraetere, DE-Heidelberg
259   Bacterially expressed nanobodies can replace secondary antibody production in animals
Dirk Görlich, DE-Göttingen
20.1  'Young Scientists' session I
Wednesday, 26 September 2018
09:35
-11:05
42   The hen’s egg test on the chick area vasculosa (HET-CAV) as a test system to evaluate the antimicrobial activity of drugs and formulations
Paul Warncke, DE-Jena
181   Comparison of Breathing Patterns for Aerosol Inhalation Using an Electro-mechanical Lung Simulator
Richard Paštěka, AT-Vienna
280   Off-target effects of novel purine-analog phosphonates for anti-cancer therapy
Christian Zoschke, DE-Berlin
19   A dynamic model of the alveolar interface for the study of aerosol deposition
Roberta Nossa
, IT-Pisa
53   Human buffy-coat derived platelet lysate: comparison of single-patient and pooled units for the cultivation of different human cell lines
Michelle Hesler, DE-Sulzbach
97   Organ-on-a-chip meets traction force microscopy: In situ characterization of forces in 3D micro-tissues
Stefanie Fuchs, DE-Stuttgart
20.2  'Young Scientists' session II
Wednesday, 26 September 2018
11:35
-13:05
103   Co-Cultivation of myofibroblasts and adipocytes provides new insights into hypertrophic scar regeneration
Katharina Hörst, DE-Berlin
128   Development of advancing human 3D trabecular meshwork models to assess onset of Glaucoma
Sara Tirendi, IT-Genova
159   3Rs in Education - Systematical Evaluation of Simulators for Rats and Mice
Melanie Humpenöder, DE-Berlin
175   Bioinformatics analysis of IPS cell data to elucidate mechanisms of actions of nephrotoxins
Pranika Singh, CH-Basel
246   SimulRator – Manufacturing a 3D-printed simulator of the rat for laboratory animal training courses
Giuliano Mario Corte, DE-Berlin
251   Chronic lymphocytic leukemia cells as an in vitro model in preclinical drug evaluation
Tijana Markovic, SI-Ljubljana
R1 Round Table I (plenary)
International Progress in 3Rs Research
Sunday, 23 September 2018

17:35-18:35
    Moderator
Erin Hill, ASCCT, US-Gaithersburg
Panelists
Shujun Cheng, CCARE, CN-Guangzhou & Shanghai
Roger Curren, IIVS, US-Gaithersburg
Stefanie Schindler, AnimalfreeResearch, CH-Bern
R2 Round Table II (plenary)
3R Centers in Europe - National and Local Centers
Monday, 24 September 2018

17:35-18:35
    Moderator
Susanna Louhimies, EU, BE-Brussels
Panelists
Arti Ahluwalia, Centro 3R, IT-Genoa
Chantra Eskes, 3RCC, CH-Bern
Ian Ragan, NC3R, GB-London
Monika Schaefer-Korting, BB3R, DE-Berlin
Stephanie Kraemer, ICar3R, DE-Giessen
Judith Lechner, MUI Animal Free Research Cluster, AT-Innsbruck
 
R3 Round Table III (plenary)
Applying human 3D models and Multi-Organ-Chips (MOCs) in Industry
Tuesday, 25 September 2018

17:35-18:35
    Moderator
Winfried Neuhaus, AIT, AT-Vienna
Panelists

Samuel Constant, Epithelix & Oncotheis, CH-Plan-les-Ouates
Helena Kandarova, MatTek, SK-Bratislava (to be confirmed)
Jochen Kuehnl, Beiersdorf, DE-Hamburg
Robert Landsiedel, BASF, DE-Ludwigshafen
Peter Ertl, Vienna University of Technology, AT-Vienna
 
P1 Poster Session I
Monday, 24 September 2018

18:35-20:00
    Survey of the posters with presence of the authors.
The titles and authors of this poster session I will be published separately.
All posters will be present during all days of the congress.
P2 Poster Session II
Tuesday, 25 September 2018

18:35-20:00
    Survey of the posters with presence of the authors.
The titles and authors of this poster session II will be published separately.
All posters will be present during all days of the congress.